News | August 01, 2024
Strides Pharma posts Q1 FY25 PAT at Rs. 68.3 Cr
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
BAV has revolutionized the animal vaccination industry with its ground-breaking delivery methods that prioritize quality, safety, and efficacy
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
GSK and Flagship to jointly fund up to $150 million upfront
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
The partnership will focus on creating capabilities for quickly and accurately processing vast amounts of clinical data
Reported profit after tax declined 19% year-on-year to Rs 76 crores
Subscribe To Our Newsletter & Stay Updated
